Pancreatic Cancer Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

Pancreatic Cancer Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

The report on the global pancreatic cancer market provides qualitative and quantitative analysis for the period from 2021-2030. The global pancreatic cancer market was valued at USD 2448.9 million in 2022 and is expected treach USD 7114.4 million in 2030, with a CAGR of 12.5% during the forecast period 2023-2030. The study on pancreatic cancer market covers the analysis of the leading geographies such as North America, Europe, Asia Pacific, and RoW for the period of 2021-2030.

Rising rates of pancreatic cancer cases and frequency drive the market for pancreatic cancer market. As per the WCRF International, “it is stated that pancreatic cancer is the 12th most common cancer worldwide. Pancreatic cancer is majorly caused due tobesity, diabetes, and extremely tall height. For instance, The International Diabetes Foundation estimates that there are 537 million people (20-79 years old) whhave diabetes worldwide. There will be 643 million diabetics globally by 2030, and there will be 783 million by 2045. Another factor fueling the demand for the pancreatic cancer market is rising government initiatives and improving healthcare infrastructure. Companies are collaborating with the government and other public organizations tcure pancreatic cancer. For instance, Servier announced today, in collaboration with the International Society for Clinical Oncology (ISCO) and the Egyptian Foundation for Medical Sciences (EFMS), the launch of its treatment for pancreatic cancer in Egypt.

The global pancreatic cancer market is bifurcated by type, treatment type, diagnosis route of administration, and distribution channel. By type, the segment is further bifurcated intexocrine and endocrine. The exocrine segment is anticipated tgrow at a faster rate than the market growth during the forecast period. Exocrine pancreatic cancer develops from exocrine cells, which make up the exocrine gland and ducts of the pancreas. Tcure Exocrine Pancreatic Cancer surgery is conducted tremove the tumor, relieve the symptoms, or prevent complications. Radiation treatments, which use X-rays tkill cancer cells. Chemotherapy is alssuggested with chemicals or drugs. Immunotherapy or biological therapy is alsan effective treatment. According tan article published on pancreatic adenocarcinoma, 90 % of pancreatic cancer is arising in the exocrine glands of the pancreas, and pancreatic neuroendocrine tumor which is less common occurs in the endocrine tissue of the pancreas.

The global pancreatic cancer market is segmented intthe Asia Pacific, North America, Europe, the Middle East & Africa, and South America. North America is predicted tbe the fastest-growing region within the global market share. The U.S. is expected thold onta sizable market share due tits high expenditures on healthcare, compassionate reimbursement procedures, and rising pancreatic cancer occurrence. According tthe National Program of Cancer Registries database,” encompassing almost 65% of the U.S. population, indicates that the incidence of pancreatic cancer is rising faster in people under the age of 55 than in people beyond the age of 55, and more quickly in women than in males. “For instance, The Advanced Research Projects Agency for Health (ARPA-H) has President Biden's bold new vision for biomedical and health research. The objective of this organization is tincrease the capacity of the American government texpedite research that can enhance human health and tincrease our capacity tprevent, detect, and treat a variety of diseases, including pancreatic cancer.

Report Findings

1) Drivers

Rising rates of pancreatic cancer cases and frequency drive the market for pancreatic cancer market.

Rising government initiatives and improving healthcare infrastructure fuels the market for pancreatic cancer treatment.

2) Restraints

High cost and side effects associated with treatment are likely thamper the pancreatic cancer market growth.

3) Opportunities

Advancements in diagnostic technology and the development of drugs fuels the pancreatic cancer market.

Research Methodology

A) Primary Research

Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include

1. Key Opinion Leaders associated with Infinium Global Research

2. Internal and External subject matter experts

3. Professionals and participants from the industry

Our primary research respondents typically include

1. Executives working with leading companies in the market under review

2. Product/brand/marketing managers

3. CXO level executives

4. Regional/zonal/ country managers

5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include

1. Company reports and publications

2. Government/institutional publications

3. Trade and associations journals

4. Databases such as WTO, OECD, World Bank, and among others.

5. Websites and publications by research agencies

Segment Covered

The global pancreatic cancer market is segmented on the basis of type, treatment type, diagnosis, route of administration, end user, and distribution channel.

The Global Pancreatic Cancer Market by Type

Exocrine

Endocrine

The Global Pancreatic Cancer Market by Treatment Type

Chemotherapy

Targeted Therapy

Immunotherapy

Hormone Therapy

Others

The Global Pancreatic Cancer Market by Diagnosis

Blood Test

Biopsy

Imaging Tests

Ultrasound

Computerized Tomography (CT) scans

Others

The Global Pancreatic Cancer Market by Route of Administration

Oral

Parenteral

Others

The Global Pancreatic Cancer Market by End User

Hospitals

Specialty Clinics

Homecare

Others

The Global Pancreatic Cancer Market by Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

Company Profiles

The companies covered in the report include

Bayer AG

Mylan (is now part of Viatris)

Teva Pharmaceutical Industries Ltd.

Sanofi

Pfizer Inc.

GSK plc

Novartis AG

Zydus Lifesciences Ltd.

AstraZeneca

Johnson & Johnson Services, Inc.

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the pancreatic cancer market.

2. Complete coverage of all the segments in the pancreatic cancer market tanalyze the trends, developments in the global market and forecast of market size up t2030.

3. Comprehensive analysis of the companies operating in the global pancreatic cancer market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.

4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus tinvest, consolidate, expand and/or diversify.